Long noncoding RNA study: Genome-wide approaches

Tao, Shuangping; Hou, Yunfei; Diao, Li-Ting; Hu, Yanxia; Xu, Wan-Yi; Xie, Shu‐Juan; Xiao, Zhilong

doi:10.1016/j.gendis.2022.10.024

Cited by 4 publications

(2 citation statements)

References 310 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, ncRNAs are divided into housekeeping ncRNAs, such as rRNAs and tRNAs, which carry out fundamental cellular functions, and regulatory ncRNAs, including miRNAs, circRNAs, and lncRNAs, which contribute to gene expression regulation. [28] Secondly, the size of ncRNAs determines their classification, distinguishing between lncRNAs that exceed 200 nucleotides in length, and small ncRNAs that are below 200 nucleotides. Notable examples of small ncRNAs include miRNAs, small interfering RNAs (siRNAs), and piwi-interacting RNAs (piR-NAs).…”

Section: Introductionmentioning

confidence: 99%

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Xu,

Zhang

et al. 2024

Medicine

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine malignancy. Although surgery can cure localized disease, but the majority of patients experience recurrence of ACC. The 5-year survival rate of patients with metastatic ACC is <15%, and the prognosis is poor. Therefore, it is urgent to explore the potential diagnostic markers and therapeutic targets for ACC. Recently, it has been proved that non-coding RNA (ncRNAs) is widely involved in pathological and physiological processes, including tumorigenesis and development. Aberrantly expressed ncRNAs have been found to be involved in the pathogenesis of ACC. Here, we summarized the expression patterns and the molecular mechanism of the involvement of microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in ACC development. To explore the clinical value of ncRNAs as noninvasive biomarkers of ACC, we also displayed the relationship between the expression level of ncRNAs and the diagnosis and prognosis of patients with ACC.

show abstract

Section: Introductionmentioning

confidence: 99%

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Xu,

Zhang

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, lncRNAs have the potential to serve as valuable biomarkers for progression and prognosis assessment, as well as promising therapeutic targets [17][18][19][20][21][22]. With the development and widespread use of highthroughput sequencing technologies, an increasing number of lncRNAs have been discovered [23][24][25][26].…”

Section: Introductionmentioning

confidence: 99%

DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy

Shu,

Xia,

Luo

et al. 2024

Int. J. Med. Sci.

View full text Add to dashboard Cite

DARS-AS1, short for Aspartyl-tRNA synthetase antisense RNA 1, has emerged as a pivotal player in cancers. Upregulation of this lncRNA is a recurrent phenomenon observed across various cancer types, where it predominantly assumes oncogenic roles, exerting influence on multiple facets of tumor cell biology. This aberrant expression of DARS-AS1 has triggered extensive research investigations, aiming to unravel its roles and clinical values in cancer. In this review, we elucidate the significant correlation between dysregulated DARS-AS1 expression and adverse survival prognoses in cancer patients, drawing from existing literature and pan-cancer analyses from The Cancer Genome Atlas (TCGA). Additionally, we provide comprehensive insights into the diverse functions of DARS-AS1 in various cancers. Our review encompasses the elucidation of the molecular mechanisms, ceRNA networks, functional mediators, and signaling pathways, as well as its involvement in therapy resistance, coupled with the latest advancements in DARS-AS1-related cancer research. These recent updates enrich our comprehensive comprehension of the pivotal role played by DARS-AS1 in cancer, thereby paving the way for future applications of DARS-AS1-targeted strategies in tumor prognosis evaluation and therapeutic interventions. This review furnishes valuable insights to advance the ongoing efforts in combating cancer effectively.

show abstract

Research Progress of lncRNA-ATB/miR-141-3p/GP73 Ax-is-Mediated EMT Promoting TACE Refractoriness

耿

2024

ACM

View full text Add to dashboard Cite

Long noncoding RNA study: Genome-wide approaches

Cited by 4 publications

References 310 publications

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy

Research Progress of lncRNA-ATB/miR-141-3p/GP73 Ax-is-Mediated EMT Promoting TACE Refractoriness

Contact Info

Product

Resources

About